PMC:7556165 / 68399-68846 JSONTXT

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T382","span":{"begin":69,"end":77},"obj":"Species"},{"id":"T383","span":{"begin":129,"end":139},"obj":"Species"},{"id":"T384","span":{"begin":129,"end":133},"obj":"Species"}],"attributes":[{"id":"A384","pred":"ncbi_taxonomy_id","subj":"T384","obj":"NCBItxid:694009"},{"id":"A382","pred":"ncbi_taxonomy_id","subj":"T382","obj":"NCBItxid:2697049"},{"id":"A383","pred":"ncbi_taxonomy_id","subj":"T383","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T403","span":{"begin":0,"end":88},"obj":"Sentence"},{"id":"T404","span":{"begin":89,"end":393},"obj":"Sentence"},{"id":"T405","span":{"begin":394,"end":447},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T148","span":{"begin":381,"end":385},"obj":"Body_part"}],"attributes":[{"id":"A148","pred":"uberon_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1868","span":{"begin":23,"end":27},"obj":"Gene"},{"id":"1869","span":{"begin":200,"end":204},"obj":"Gene"},{"id":"1870","span":{"begin":129,"end":139},"obj":"Species"},{"id":"1871","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"1872","span":{"begin":214,"end":223},"obj":"Disease"},{"id":"1873","span":{"begin":381,"end":392},"obj":"Disease"}],"attributes":[{"id":"A1871","pred":"pubann:denotes","subj":"1871","obj":"MESH:C000657245"},{"id":"A1870","pred":"pubann:denotes","subj":"1870","obj":"Tax:2697049"},{"id":"A1868","pred":"pubann:denotes","subj":"1868","obj":"Gene:59272"},{"id":"A1872","pred":"pubann:denotes","subj":"1872","obj":"MESH:D007239"},{"id":"A1869","pred":"pubann:denotes","subj":"1869","obj":"Gene:59272"},{"id":"A1873","pred":"pubann:denotes","subj":"1873","obj":"MESH:D055370"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T6119","span":{"begin":23,"end":27},"obj":"Protein"},{"id":"T6120","span":{"begin":200,"end":204},"obj":"Protein"}],"attributes":[{"id":"A6119","pred":"uniprot_id","subj":"T6119","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A6120","pred":"uniprot_id","subj":"T6120","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T273","span":{"begin":214,"end":223},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T274","span":{"begin":313,"end":317},"obj":"http://purl.obolibrary.org/obo/IDO_0000531"},{"id":"T275","span":{"begin":318,"end":322},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T276","span":{"begin":350,"end":361},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T449","span":{"begin":318,"end":322},"obj":"Body_part"},{"id":"T450","span":{"begin":381,"end":385},"obj":"Body_part"}],"attributes":[{"id":"A449","pred":"fma_id","subj":"T449","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A450","pred":"fma_id","subj":"T450","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T401","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"T402","span":{"begin":129,"end":139},"obj":"Disease"},{"id":"T403","span":{"begin":129,"end":133},"obj":"Disease"},{"id":"T404","span":{"begin":214,"end":223},"obj":"Disease"},{"id":"T405","span":{"begin":386,"end":392},"obj":"Disease"}],"attributes":[{"id":"A402","pred":"mondo_id","subj":"T402","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A405","pred":"mondo_id","subj":"T405","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A403","pred":"mondo_id","subj":"T403","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A401","pred":"mondo_id","subj":"T401","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A404","pred":"mondo_id","subj":"T404","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T134","span":{"begin":381,"end":385},"obj":"http://purl.obolibrary.org/obo/MAT_0000135"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T144","span":{"begin":344,"end":361},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T145","span":{"begin":344,"end":361},"obj":"http://purl.obolibrary.org/obo/GO_0019079"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T149","span":{"begin":344,"end":361},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T150","span":{"begin":344,"end":361},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1868","span":{"begin":23,"end":27},"obj":"Gene"},{"id":"1869","span":{"begin":200,"end":204},"obj":"Gene"},{"id":"1870","span":{"begin":129,"end":139},"obj":"Species"},{"id":"1871","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"1872","span":{"begin":214,"end":223},"obj":"Disease"},{"id":"1873","span":{"begin":381,"end":392},"obj":"Disease"}],"attributes":[{"id":"A1868","pred":"tao:has_database_id","subj":"1868","obj":"Gene:59272"},{"id":"A1869","pred":"tao:has_database_id","subj":"1869","obj":"Gene:59272"},{"id":"A1870","pred":"tao:has_database_id","subj":"1870","obj":"Tax:2697049"},{"id":"A1871","pred":"tao:has_database_id","subj":"1871","obj":"MESH:C000657245"},{"id":"A1872","pred":"tao:has_database_id","subj":"1872","obj":"MESH:D007239"},{"id":"A1873","pred":"tao:has_database_id","subj":"1873","obj":"MESH:D055370"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}

{"project":"LitCovid-sentences","denotations":[{"id":"T403","span":{"begin":0,"end":88},"obj":"Sentence"},{"id":"T404","span":{"begin":89,"end":393},"obj":"Sentence"},{"id":"T405","span":{"begin":394,"end":447},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As evidence builds up, ACE2 rapidly emerged as a specific target for COVID-19 treatment. Since this enzyme was identified as the SARS-CoV-2 receptor (Zhou et al., 2020), several approaches to address ACE2 mediated infection have been described (Li Y. et al., 2020; Zhang H. et al., 2020), with the aim to prevent host cell entry and subsequent viral replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):"}